Associated Papers
Revealing conformational changes of GTP-bound NRAS mutants probed by GaMD and Markov state models.
Zhao L et al.
Physical Chemistry Chemical Physics : Pccp, 2026
Dysregulation of the PATZ1/CTCF Balance Silences ZBTB20 to Drive Melanoma Progression.
Deng C et al.
Advanced Science (weinheim, Baden-wurttemberg, Germany), 2026
Impact of KRAS-G12 Mutations on the KRAS-GTP Bound Conformational Dynamics: Structure, Free Energy Barriers and Drugging Pockets.
Hu Z et al.
Jacs Au, 2026
Unveiling a new SORBS2::BRAF fusion in papillary thyroid carcinoma: insights from molecular diagnostics.
Dai Y et al.
Virchows Archiv : an International Journal of Pathology, 2026
A Real-Time, Programmable, and Multiplex Ligation Chain Reaction-MNAzyme Platform for Single-Nucleotide Variant Detection.
Zhang J et al.
Analytical Chemistry, 2026
Targeting SHOC2: a treatable therapeutic site in RAS(Q61) mutant cancers.
Tang J et al.
Science China. Life Sciences, 2026
Malignant struma ovarii: Advances in molecular pathogenesis, classification, diagnosis and treatment.
Lin W et al.
Histopathology, 2026
Differential Preclinical Efficacy of Combined CDK4/6 and MEK Inhibition in Low-Grade Serous Ovarian Carcinoma Based on KRAS/NF1 Mutational Status.
Bittner M et al.
International Journal of Molecular Sciences, 2026
Clinical outcomes of genomically guided trametinib monotherapy across cancer types: results from the IMPRESS-Norway trial.
Slørdahl KS et al.
Acta Oncologica (stockholm, Sweden), 2026
Infantile Congenital Nevus With Atypical Proliferative Nodules and NTRK Gene Fusion.
Xue S et al.
Journal of Cutaneous Pathology, 2026
Integrated mutational landscape analysis of endometrial stromal sarcoma.
Hartwich TMP et al.
Proceedings of the National Academy of Sciences of the United States of America, 2026
BRAFV600E and NRASQ61R Antibodies Are Sensitive and Specific Diagnostic Biomarkers for BRAF and NRAS Mutations in Conjunctival Melanomas.
Tauziède-Espariat A et al.
The American Journal of Dermatopathology, 2026
Genomic Profiling of Pediatric Solid Tumors With a Dual DNA/RNA Panel: JCCG-TOP2 Study.
Tao K et al.
Cancer Science, 2026
Using the Reactome Graph Database to generate pathway fingerprints for cancer-related genes, and using the fingerprints to gain insights into cancer, comorbidity, and cancer gene networks.
Iengar P et al.
Computational Biology and Chemistry, 2026
Oncogenic NRAS Mutation in Incipient Sarcomatous Transformation of Cystic Nephroma From a Patient With DICER1-Related Tumor Predisposition Syndrome.
Cortes-Santiago N et al.
Pediatric Blood & Cancer, 2026
Insights into RAS-driven melanoma and its therapeutic implications.
Chatziioannou E et al.
Cancer Treatment Reviews, 2026
CFT1946 Is an Orally Available Brain-Penetrant BRAFV600-Mutant Degrader That Overcomes BRAF Inhibitor Resistance.
Kreger BT et al.
Cancer Research, 2026
Small Nucleotide Variant Analysis Using RNA Fusion Panel (SMURF): Making the Most of RNAseq Data in Solid Tumours.
Dorwal P et al.
Journal of Clinical Laboratory Analysis, 2026
Structure of SHOC2-KRAS-PP1C complex reveals RAS isoform-specific determinants and insights into targeting complex assembly by RAS inhibitors.
Bonsor DA et al.
Nature Communications, 2026
RAS(ON) Multiselective Inhibition Drives Antitumor Immunity in Preclinical Models of NRAS-Mutant Melanoma.
Anastacio Da Costa Carvalho L et al.
Cancer Immunology Research, 2026
Decoding the Mutational Hierarchy of Thyroid Cancer and Associated Signaling Pathways.
Nashier D et al.
Archives of Medical Research, 2026
Genetic Evolution of Melanoma: Comparative Analysis of Candidate Gene Mutations in Healthy Skin, Nevi, and Tumors from the Same Patients.
Gil-Barrachina M et al.
International Journal of Molecular Sciences, 2026
RAS Mutation-Specific Responses to Paralog- and State-Selective RAS Inhibitors.
Baars B et al.
Molecular Cancer Research : Mcr, 2026
Chromophobe thyroid carcinoma: a distinct entity associated with TSC gene alterations.
Harahap AS et al.
Virchows Archiv : an International Journal of Pathology, 2026
Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia.
Brown JR et al.
Blood, 2026
Malignancy Risk, Molecular Mutations, and Surgical Outcomes of Thyroid Nodules Classified as Atypia of Undetermined Significance in the Bethesda System: A Comprehensive Analysis.
Bourque C et al.
Cytopathology : Official Journal of the British Society for Clinical Cytology, 2026
Efficacy and Safety of Trametinib Therapy for Complex Lymphatic Malformations.
Xu Y et al.
Pediatric Blood & Cancer, 2026
Vascular malformations: from genetics to therapeutics.
Morin G et al.
Embo Molecular Medicine, 2026
Melanomas and Mesenchymal Tumors Arising in Giant Congenital Melanocytic Nevi: Clinico-Pathological and Molecular Characterization of a Case Series.
Rossi S et al.
Pigment Cell & Melanoma Research, 2026
The Occurrence of Gene Fusions in Thyroid Lesions and the Relation With Chronic Lymphocytic Thyroiditis.
Jentus MM et al.
Pathology International, 2026
MAPK Pathway Mutations Emerge in Mutant-IDH1 Inhibitor-Resistant Cholangiocarcinoma and Attenuate the Interferon Response.
Wan J et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
Adamantinoma-like Ewing sarcoma with NRAS Q61R mutation-a hitherto unreported mutation in a case from the nasal cavity.
Wu B et al.
Virchows Archiv : an International Journal of Pathology, 2025
Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in NRAS-Mutated Melanoma.
Foth M et al.
Biorxiv : the Preprint Server for Biology, 2025
Somatic Mutational Landscape in Follicular Thyroid Cancer: Insights from AACR GENIE Data.
Hsia B et al.
Journal of Personalized Medicine, 2025
Complex genetic landscape in CLL: Clinical impact on patients' survival and insights into the altered molecular pathways.
Caputo C et al.
Molecular Therapy. Oncology, 2025
Evaluation of the genetic alterations landscape of differentiated thyroid cancer in children.
Çetiner EB et al.
Journal of Pediatric Endocrinology & Metabolism : Jpem, 2025
Clonal architecture of FLT3-ITD and acquired 13q uniparental disomy define prognostic heterogeneity and therapeutic vulnerabilities in acute myeloid leukemia.
Lai A et al.
Neoplasia (new York, N.y.), 2025
Widespread Epistasis between Cancer Driver Mutations and Allele-Specific Copy Number Variations.
Merzliakov S et al.
Biorxiv : the Preprint Server for Biology, 2025
Oral Melanocytic Neoplasms: A Narrative Review.
Maldonado-Mendoza J
Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 2025
Molecular profiling and tumour biomarker analysis of GOG281/LOGS: a positive late-phase trial of trametinib for recurrent/persistent low grade-serous ovarian cancer.
Hollis RL et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
Ultrasensitive Detection of Rare Mutations via Amplifying-Cleaving-Enriching in Acute Myeloid Leukemia.
Zhuang X et al.
Biomedicines, 2025
CDKN2A homozygous deletions and TSC2 somatic mutations in metastatic pancreatic neuroendocrine tumors.
Jesus TT et al.
Npj Precision Oncology, 2025
A New Case Linking a Somatic NRAS Variant to Encephalocraniocutaneous Lipomatosis.
Azrak O et al.
American Journal of Medical Genetics. Part A, 2025
Evaluation of Long-Read Genome Sequencing for Genomic Profiling of Myeloid Cancers.
Abel HJ et al.
The Journal of Molecular Diagnostics : Jmd, 2025